A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)
Phase of Trial: Phase II
Latest Information Update: 31 Jan 2019
At a glance
- Drugs Filgotinib (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 07 Jun 2018 This trial has been completed in Poland.
- 09 Apr 2018 Planned End Date changed from 1 Jun 2019 to 1 Mar 2020.
- 09 Apr 2018 Planned primary completion date changed from 1 May 2019 to 1 Mar 2020.